Focused On-demand Library for Large ribosomal subunit protein uL18m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H0U6

UPID:

RM18_HUMAN

Alternative names:

39S ribosomal protein L18, mitochondrial

Alternative UPACC:

Q9H0U6; Q5TAP9; Q9NZW8

Background:

Large ribosomal subunit protein uL18m, alternatively known as 39S ribosomal protein L18, mitochondrial, plays a pivotal role in cellular function. It collaborates with thiosulfate sulfurtransferase to facilitate the mitochondrial import of cytosolic 5S rRNA. Its precursor form exhibits RNA chaperone activity, crucial for folding 5S rRNA into a conformation suitable for import, recognized by rhodanese. This protein's ability to bind the helix IV-loop D in the gamma domain of 5S rRNA underscores its significance in RNA processing.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein uL18m could open doors to potential therapeutic strategies.